Pioglitazone enhances small-sized adipocyte proliferation in subcutaneous adipose tissue

Kajita, Kazuo; Mori, Ichiro; Hanamoto, Takayuki; Ikeda, Takahide; Fujioka, Kei; Yamauchi, Masahiro; Okada, Hironao; Usui, Toshio; Takahashi, Noriko; Kitada, Yoshihiko; Taguchi, Kohichiro; Kajita, Toshiko; Uno, Yoshihiro; Morita, Hiroyuki; Ishizuka, Tatsuo

doi:10.1507/endocrj.ej12-0259

Cited by 20 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in conformity to earlier studies, that demonstrated similarly high prevalence of asymptomatic CTS among patients with diabetes[12]. …”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Effect of pioglitazone on nerve conduction velocity of the median nerve in the carpal tunnel in type 2 diabetes patients

Chatterjee¹,

Sanyal²,

Choudhury³

et al. 2016

WJD

View full text Add to dashboard Cite

AIMTo evaluate the impact of pioglitazone pharmacotherapy in median nerve electrophysiology in the carpal tunnel among type 2 diabetes patients.METHODSThe study was executed in patients with type 2 diabetes, treated with oral drugs, categorized under pioglitazone or non-pioglitazone group (14 in each group), and who received electrophysiological evaluation by nerve conduction velocity at baseline and 3 mo.RESULTSAt 3 mo, pioglitazone-category had inferior amplitude in sensory median nerve [8.5 interquartile range (IQR) = 6.5 to 11.5) vs non-pioglitazone 14.5 (IQR 10.5 to 18.75)] (P = 0.002). Non-pioglitazone category displayed amelioration in amplitude in the sensory median nerve [baseline 13 (IQR = 9 to 16.25) vs 3 mo 8.5 (IQR = 6.5 to 11.5)] (P = 0.01) and amplitude in motor median nerve [baseline 9 (IQR = 4.75 to 11) vs 3 mo 6.75 (IQR = 4.75 to 10.25)] (P = 0.049); and deterioration of terminal latency of in motor ulnar nerve [baseline 2.07 (IQR = 1.92 to 2.25) vs 3 mo 2.16 (IQR = 1.97 to 2.325)] (P = 0.043). There was amelioration of terminal latency in sensory ulnar nerve [baseline 2.45 (IQR = 2.315 to 2.88) vs 3 mo 2.37 (IQR = 2.275 to 2.445) for pioglitazone group (P = 0.038).CONCLUSIONTreatment with pioglitazone accentuates probability of compressive neuropathy. In spite of comparable glycemic control over 3 mo, patients treated with pioglitazone showed superior electrophysiological parameters for the ulnar nerve. Pioglitazone has favourable outcome in nerve electrophysiology which was repealed when the nerve was subjected to compressive neuropathy.

show abstract

“…This was in conformity to earlier studies, that demonstrated similarly high prevalence of asymptomatic CTS among patients with diabetes[12]. …”

Section: Discussionsupporting

confidence: 93%

“…Preclinical studies show that pioglitazone produces an increase in subcutaneous adipocyte surface and whole body adipocity[10,11]. Although mature visceral adipocytes have a greater propensity to proliferate than subcutaneous adipocytes, it is the latter that proliferates following pioglitazone treatment[12,13]. …”

Section: Discussionmentioning

confidence: 99%

Effect of pioglitazone on nerve conduction velocity of the median nerve in the carpal tunnel in type 2 diabetes patients

Chatterjee¹,

Sanyal²,

Choudhury³

et al. 2016

WJD

View full text Add to dashboard Cite

show abstract

“…Furthermore, the primary function of PGZ is to increase the IMF deposition, and improvement of the meat flavor and taste has already been proven in pigs . Intensive research has ascribed the mechanism to the role of PGZ as an affinity ligand of PPAR γ , promoting adipocyte proliferation and fat accumulation . Undoubtedly, we found that supplementation with 7.5 mg kg −1 PGZ and 15 mg kg −1 PGZ increased the IMF by 14.14% and 20.37%, respectively.…”

Section: Discussionmentioning

confidence: 64%

“…28 Intensive research has ascribed the mechanism to the role of PGZ as an affinity ligand of PPAR , promoting adipocyte proliferation and fat accumulation. 29,30 Undoubtedly, we found that supplementation with 7.5 mg kg −1 PGZ and 15 mg kg −1 PGZ increased the IMF by 14.14% and 20.37%, respectively. In this regard, the drip loss, cooking loss, and shear force displayed a negative correlation but positive effects with 15 mg kg −1 PGZ supplementation.…”

Section: Discussionmentioning

confidence: 73%

Dietary supplementation with pioglitazone hydrochloride improves intramuscular fat, fatty acid profile, and antioxidant ability of thigh muscle in yellow‐feathered chickens

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Muscle fat content and fatty acid composition play an important role in poultry flavor and taste. To investigate the effects of pioglitazone hydrochloride (PGZ) on growth performance and thigh muscle quality in yellow‐feathered chickens, 360 female chickens were randomly divided into three groups and treated with three doses of PGZ (0, 7.5, and 15 mg kg−1) for 28 days. Each group had six replicates of 20 chickens. RESULTS The results showed that dietary supplementation with 15 mg kg−1 PGZ increased average daily feed intake (ADFI) and the average daily gain (ADG) from 0 to 14 days. Furthermore, the triglyceride (TG) level was decreased by 15 mg kg−1 PGZ, whereas the eviscerated yield was increased. The relative weight of the heart and kidneys showed a linear increase with dietary PGZ supplementation, and the drip loss of the thigh muscle was significantly decreased by 15 mg kg−1 PGZ supplementation. Moreover, a* value, intramuscular fat (IMF), and polyunsaturated fatty acids (PUFAs) showed a linear increase, and pH24 h and drip loss showed a quadratic influence with the levels of PGZ supplementation. In particular, the PUFA proportion was increased by 7.63% and 9.14% in the 7.5 mg kg−1 PGZ and 15 mg kg−1 PGZ groups, respectively. Additionally, 15 mg kg−1 of PGZ increased the total antioxidant capacity (T‐AOC) and glutathione peroxidase (GSH‐PX) activity. CONCLUSION In summary, 15 mg kg−1 PGZ has substantial effects on growth performance and meat quality, particularly by decreasing drip loss and increasing IMF content, PUFA proportions, and antioxidant ability. © 2019 Society of Chemical Industry

show abstract

“…Moreover, primary cultured adipocytes using ceiling culture showed an increase in cell number and incorporated BrdU. We have found that BrdU is incorporated more actively in small adipocytes (<20 µm in diameter) than large ones [12] in histological examination. However, it was hard to discriminate these cells from non-adipocytes.…”

Section: Growth Of Adipose Tissue In Leto and Oletf Ratsmentioning

confidence: 80%

The role of small proliferative adipocytes in the development of obesity: Comparison between Otsuka Long-Evans Tokushima Fatty (OLETF) rats and non-obese Long-Evans Tokushima Otsuka (LETO) rats

et al. 2013

Self Cite

View full text Add to dashboard Cite

Obesity consists of hypertrophy and hyperplasia of adipocytes. Although the number of adipocytes is influenced by anatomical location, nutritional environment, hormone and genetic variation, it has been thought to be determined by the proliferation of precursor cells and subsequent differentiation. However, our recent research has identified the population of small adipocytes less than 20 μm in diameter, exhibiting tiny or no lipid droplets and expressing adipocyte marker proteins (small proliferative adipocytes: SPA) in isolated adipocytes. Notably, 5-bromo-2'-deoxyuridine (BrdU) incorporation and proliferating cell nuclear antigen (PCNA) expression were detected in these cells. In this study, we investigated the role of SPA in development of adipose tissue using genetically obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats and their non-obese and non-diabetic littermates, Long-Evans Tokushima Otsuka (LETO) rats. Proliferation of SPA was determined by measurement of PCNA at the protein level in isolated fractions of adipocytes with collagenase digestion. In general, expression levels of PCNA rose, reached a maximum, and declined in adipose tissues during aging. The expression levels of PCNA were maximum in epididymal fat at 32 w and 12 w of age in LETO and OLETF, respectively. They reached the maximum at 20 w of age both in LETO and OLETF in mesenteric fat. Although the PCNA expression level was higher in OLETF in the early period, it reversed later. Enlargement of adipocytes developed during aging, which was enhanced when the expression levels of PCNA declined. These results suggest that proliferation of SPA may prevent adipocyte hypertrophy and the resultant development of metabolic disorders.

show abstract

Pioglitazone enhances small-sized adipocyte proliferation in subcutaneous adipose tissue

Cited by 20 publications

References 21 publications

Effect of pioglitazone on nerve conduction velocity of the median nerve in the carpal tunnel in type 2 diabetes patients

Effect of pioglitazone on nerve conduction velocity of the median nerve in the carpal tunnel in type 2 diabetes patients

Dietary supplementation with pioglitazone hydrochloride improves intramuscular fat, fatty acid profile, and antioxidant ability of thigh muscle in yellow‐feathered chickens

The role of small proliferative adipocytes in the development of obesity: Comparison between Otsuka Long-Evans Tokushima Fatty (OLETF) rats and non-obese Long-Evans Tokushima Otsuka (LETO) rats

Contact Info

Product

Resources

About